135 related articles for article (PubMed ID: 35294204)
1. Machine Learning Analysis of Cocaine Addiction Informed by DAT, SERT, and NET-Based Interactome Networks.
Feng H; Gao K; Chen D; Shen L; Robison AJ; Ellsworth E; Wei GW
J Chem Theory Comput; 2022 Apr; 18(4):2703-2719. PubMed ID: 35294204
[TBL] [Abstract][Full Text] [Related]
2. Proteome-Informed Machine Learning Studies of Cocaine Addiction.
Gao K; Chen D; Robison AJ; Wei GW
J Phys Chem Lett; 2021 Nov; 12(45):11122-11134. PubMed ID: 34752088
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference.
Sora I; Hall FS; Andrews AM; Itokawa M; Li XF; Wei HB; Wichems C; Lesch KP; Murphy DL; Uhl GR
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5300-5. PubMed ID: 11320258
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.
Dutta AK; Fei XS; Beardsley PM; Newman JL; Reith ME
J Med Chem; 2001 Mar; 44(6):937-48. PubMed ID: 11300876
[TBL] [Abstract][Full Text] [Related]
5. Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity.
Miller GM; Yatin SM; De La Garza R; Goulet M; Madras BK
Brain Res Mol Brain Res; 2001 Feb; 87(1):124-43. PubMed ID: 11223167
[TBL] [Abstract][Full Text] [Related]
6. Serotonin, dopamine and norepinephrine transporter mRNAs: heterogeneity of distribution and response to 'binge' cocaine administration.
Burchett SA; Bannon MJ
Brain Res Mol Brain Res; 1997 Oct; 49(1-2):95-102. PubMed ID: 9387868
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.
Han DD; Gu HH
BMC Pharmacol; 2006 Mar; 6():6. PubMed ID: 16515684
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters.
Ravna AW; Sylte I; Dahl SG
J Pharmacol Exp Ther; 2003 Oct; 307(1):34-41. PubMed ID: 12944499
[TBL] [Abstract][Full Text] [Related]
9. Machine-learning analysis of opioid use disorder informed by MOR, DOR, KOR, NOR and ZOR-based interactome networks.
Feng H; Elladki R; Jiang J; Wei GW
Comput Biol Med; 2023 May; 157():106745. PubMed ID: 36924727
[TBL] [Abstract][Full Text] [Related]
10. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters.
Shen HW; Hagino Y; Kobayashi H; Shinohara-Tanaka K; Ikeda K; Yamamoto H; Yamamoto T; Lesch KP; Murphy DL; Hall FS; Uhl GR; Sora I
Neuropsychopharmacology; 2004 Oct; 29(10):1790-9. PubMed ID: 15226739
[TBL] [Abstract][Full Text] [Related]
11. Nonhuman primate neuroimaging and cocaine medication development.
Howell LL
Exp Clin Psychopharmacol; 2008 Dec; 16(6):446-57. PubMed ID: 19086766
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.
Simonson B; Morani AS; Ewald AW; Walker L; Kumar N; Simpson D; Miller JH; Prisinzano TE; Kivell BM
Br J Pharmacol; 2015 Jan; 172(2):515-31. PubMed ID: 24641310
[TBL] [Abstract][Full Text] [Related]
13. 2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α
Halberstadt AL; Brandt SD; Walther D; Baumann MH
Psychopharmacology (Berl); 2019 Mar; 236(3):989-999. PubMed ID: 30904940
[TBL] [Abstract][Full Text] [Related]
14. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
Verrico CD; Miller GM; Madras BK
Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
[TBL] [Abstract][Full Text] [Related]
15. The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter.
Gannon BM; Baumann MH; Walther D; Jimenez-Morigosa C; Sulima A; Rice KC; Collins GT
Neuropsychopharmacology; 2018 Nov; 43(12):2399-2407. PubMed ID: 30305739
[TBL] [Abstract][Full Text] [Related]
16. Cocaine-conditioned locomotion in dopamine transporter, norepinephrine transporter and 5-HT transporter knockout mice.
Hall FS; Li XF; Randall-Thompson J; Sora I; Murphy DL; Lesch KP; Caron M; Uhl GR
Neuroscience; 2009 Sep; 162(4):870-80. PubMed ID: 19482066
[TBL] [Abstract][Full Text] [Related]
17. Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.
Conti MM; Meadows SM; Melikhov-Sosin M; Lindenbach D; Hallmark J; Werner DF; Bishop C
Neuropharmacology; 2016 Nov; 110(Pt A):125-134. PubMed ID: 27452719
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms underlying the rewarding effects of cocaine.
Hall FS; Sora I; Drgonova J; Li XF; Goeb M; Uhl GR
Ann N Y Acad Sci; 2004 Oct; 1025():47-56. PubMed ID: 15542699
[TBL] [Abstract][Full Text] [Related]
19. Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
Cao J; Kulkarni SS; Husbands SM; Bowen WD; Williams W; Kopajtic T; Katz JL; George C; Newman AH
J Med Chem; 2003 Jun; 46(13):2589-98. PubMed ID: 12801223
[TBL] [Abstract][Full Text] [Related]
20. The SERT Met172 Mouse: An Engineered Model To Elucidate the Contributions of Serotonin Signaling to Cocaine Action.
Simmler LD; Blakely RD
ACS Chem Neurosci; 2019 Jul; 10(7):3053-3060. PubMed ID: 30817127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]